



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 31 MARCH 2018

	31 March 2018	31 March 2017
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	13,255	11,176
Adjustments for:		
Depreciation of property, plant and equipment	5,482	5,433
Interest income	(445)	(715)
Finance costs	1,458	1,313
<i>Operating profit before changes in working capital</i>	19,750	17,207
Change in inventories	4,909	(3,967)
Change in receivables, deposits and prepayments	(52,895)	(21,202)
Change in payables and accruals	7,903	11,580
<i>Cash generated from operations</i>	(20,333)	3,618
Finance costs paid	(1,458)	(1,313)
Interest income	445	715
Income tax paid	(936)	(3,656)
Net cash generated from operating activities	(22,282)	(636)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(19,378)	(15,593)
Acquisition of intangible assets	(544)	(548)
Net cash used in investing activities	(19,922)	(16,141)
Cash flows from financing activities		
Drawdown of borrowings	22,932	13,614
Net cash used in financing activities	22,932	13,614
Net increase in cash and cash equivalents	(19,272)	(3,163)
Cash and cash equivalents at 1 January	96,021	114,814
Cash and cash equivalents as at 31 March	76,749	111,651

(I) Cash and cash equivalents comprise:

	RM '000	RM '000
Cash and bank balances	47,231	40,171
Deposits placed with licensed financial institutions	29,518	71,480
	76,749	111,651

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2017 and the accompanying explanatory notes attached to the interim financial statements.)